[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100486141":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":61,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":25,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"hybrid ablation","EXPERIMENTAL","Participants in this group will receive concomitant thoracoscopic epicardial ablation and catheter endocardial ablation",[13],"Procedure: hybrid ablation",{"label":15,"type":16,"description":17,"interventionNames":18},"catheter ablation","ACTIVE_COMPARATOR","Participants in this group will receive catheter endocardial ablation only",[19],"Procedure: catheter ablation",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","simultaneous thoracoscopic epicardial and catheter endocardial ablation",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"catheter endocardial ablation",[15],[30],{"name":31,"affiliation":32,"role":33},"Zhe Zheng, MD.PhD","Chinese Academy of Medical Sciences, Fuwai Hospital","STUDY_CHAIR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","+86-010-88396051","zhengzhe@fuwai.com",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Yajie Tang, MD.PhD","+8618813019554","tangyajietangyajie@126.com",[44],{"facility":45,"status":46,"city":47,"state":25,"zip":25,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","China","CN",{"type":51,"coordinates":52},"Point",[53,54],116.39723,39.9075,{"lat":54,"lon":53},[57,59],{"name":58,"role":36,"phone":37,"phoneExt":25,"email":38},"Zhe Zheng, MD,PhD",{"name":60,"role":36,"phone":41,"phoneExt":25,"email":42},"Yajie Tang, MD,PhD",{"type":62,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100486141","concomitant-hybrid-versus-catheter-ablation-for-atrial-fibrillation-with-hypertrophic-cardiomyopathy-100486141",false,"NCT05610215","Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy","Concomitant Hybrid Versus Catheter Ablation for Reinforcing Therapeutic Effect of Atrial Fibrillation With Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. Patients' age is ≥18 y\n2. Clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment thickness ≥15 mm in genetical negative (or unknown genetical status) patients or ≥13mm in genetical positive ones-as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging or computed tomography)-that is not explained solely by loading conditions)\n3. Non-obstructed left ventricular outflow obstruction with peak gradients \\\u003C30mmHg\n4. Concomitant with persistent atrial fibrillation (7 days\\\u003Csustained episode lasting\\\u003C3 years) with drug-refractory symptoms.\n5. Be able to understand the contents of the trial, and provide written informed consent to participate in this investigation.\n\nExclusion Criteria:\n\n1. Patients with left atrial size \\>60 mm (2-dimensional echocardiography, parasternal long-axis view)\n2. Contraindicated to systemic anticoagulation\n3. Left ventricular ejection fraction ≤40%\n4. Concomitant with left atrium or left atrial appendage emboli\n5. Concomitant with a coronary or valvular disease that indicates intervention\n6. Ischaemic stroke within 2 months\n7. Previous ablation history\n8. Uncontrolled hyper\u002Fhypothyroidism\n9. End-staged kidney failure\n10. Concomitantly involved in other trials\n11. Pregnant or breastfeeding, or women of childbearing age not using a reliable contraceptive method\n12. Concomitant with bacteremia or at an active phase of infection\n13. Anatomically not suitable for thoracoscopic surgery(history of chest surgery or radiotherapy, etc.)\n14. Unwilling or unable to comply with all peri-ablation and follow-up requirements","ALL","18 Years",{"count":73,"type":74},66,"ESTIMATED","INTERVENTIONAL",[77],"NA","The goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.",[80,81,82],"Atrial Fibrillation","Cardiomyopathy, Hypertrophic","Radiofrequency Ablation","2024-08-28",{"date":85,"type":86},"2024-08-30","ACTUAL",{"date":88,"type":86},"2023-02-11",{"date":90,"type":74},"2026-12",{"name":5,"class":6},1]